Personalis Inc. Stock News

Personalis press release (PSNL): Q4 GAAP EPS of -$0.45 beats by $0.05.Revenue of $20.68M (+2.5% Y/Y) in-line.Full year 2022 OutlookTotal company revenue is expected to be…

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended December 31, 2021. Fourth Quarter and Recent Highlights Reported quarterly revenue of $20.7 million in the fourth quarter of 2021 compared with $20.2 million in the fourth quarter of 2020, a 3% increase Revenue from biopharma and other customers, excluding the VA MVP (as defined below), of $15.4 mi

Geode Capital Management LLC grew its position in Personalis, Inc. by 5.0% during the 3rd quarter, Holdings Channel.com reports. The firm owned 571,369 shares of the company''s…

Personalis (NASDAQ:PSNL) is scheduled to announce Q4 earnings results on Thursday, February 24th, after market close.The consensus EPS Estimate is -$0.50 (-47.1% Y/Y) and the…

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022 at 2:10 p.m. Eastern Time. About Personalis Personalis, Inc. is a leader in advanced cancer genomics for enabling the next generation of precision cancer therapies and diagnostics. The Personalis NeXT Platform® is designed to adapt to the complex and evolving

Personalis (PSNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its fourth quarter and full-year 2021

Personalis has seen a full boom and bust cycle again over the past year. Growth has slowed down and losses have increased, but fortunately the commercial side of the operations has seen a boost.

After three consecutive sessions of losses, Personalis <> has recovered after the company reported preliminary revenue figures for the fourth quarter and full-year 2021 that beat

Personalis, Inc. (NASDAQ:PSNL) insider Richard Chen sold 1,563 shares of the stock in a transaction dated Friday, December 17th. The stock was sold at an average price of $12.80, for a total transaction of $20,006.40. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Richard Chen []

Personalis, Inc. (NASDAQ:PSNL) has been assigned an average recommendation of Hold from the ten analysts that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company. The average 1 year target price []

Personalis, Inc. CEO John Stephen West sold 97,268 shares of the business''s stock in a transaction dated Thursday, December 16th. The stock was sold at an average price of

Personalis, Inc. (NASDAQ:PSNL) was the recipient of a large growth in short interest during the month of November. As of November 30th, there was short interest totalling 1,780,000 shares, a growth of 29.0% from the November 15th total of 1,380,000 shares. Based on an average daily volume of 413,500 shares, the days-to-cover ratio is presently []

Personalis, Inc. (NASDAQ:PSNL)s stock price rose 6.7% on Friday . The stock traded as high as $13.77 and last traded at $13.76. Approximately 26,565 shares changed hands during mid-day trading, a decline of 96% from the average daily volume of 647,558 shares. The stock had previously closed at $12.89. PSNL has been the topic of []